Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tarextumab

A monoclonal antibody directed against the Notch receptor with potential antineoplastic activity. Tarextumab binds to Notch on the cell surface… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human… Expand
2019
2019
Purpose: Both EGFR and PI3K-Akt signaling pathways have been used as therapeutically actionable targets, but resistance is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
SummaryPurpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2017
2017
An anti-EGFR/Notch antibody limits acquired resistance to EGFR inhibitors and radiation by reducing tumor-initiating cell… Expand
2017
2017
279Background: Tarextumab (TRXT), fully human IgG2 antibody inhibits signaling of Notch2/ 3 receptors. Tumor regression seen in… Expand
2016
2016
8564Background: Notch signaling is implicated in cancer stem cell self-renewal and proliferation, thus it is an appealing target… Expand
Highly Cited
2015
Highly Cited
2015
Purpose: The Notch pathway plays an important role in both stem cell biology and cancer. Dysregulation of Notch signaling has… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
7508 Background: Notch signaling is implicated in cancer stem cell self-renewal and proliferation; thus being an appealing target… Expand
2015
2015
278 Background: Tarextumab (TRXT), fully human IgG2 antibody, inhibits signaling Notch 2, 3 receptors. Tumor regression seen in… Expand
Review
2014
Review
2014
Over 100 years have passed since the first observation of the notched wing phenotype in Drosophila melanogaster, and significant… Expand
  • figure 1
  • figure 2